Table 4.
Mean (range) percentage of patients with coronary heart disease treated with specified drugs at baseline and follow up, by trial group
| Audit group (n=7) | GP recall group (n=7) | Nurse recall group (n=7) | P value for difference between groups* | |||
|---|---|---|---|---|---|---|
| Hypotensive: | ||||||
| Baseline | 67 (54-84) | 71 (56-80) | 65 (54-71) | 0.35 | ||
| Follow up | 70 (61-83) | 73 (64-83) | 66 (58-75) | |||
| Lipid lowering: | ||||||
| Baseline | 25 (14-37) | 24 (17-48) | 23 (17-27) | 0.63 | ||
| Follow up | 37 ( 9-64) | 41 (26-68) | 40 (38-45) | |||
| Antiplatelets†: | ||||||
| Baseline | 62 (44-77) | 73 (57-85) | 66 (48-74) | 0.017‡ | ||
| Follow up | 74 (55-84) | 80 (68-92) | 85 (81-89) |
Mean percentages are weighted by number of patients with coronary heart disease in each practice.
*
Based on means adjusted for baseline.
†
Among the 1754 patients with no contraindication recorded at baseline or follow up.
‡
Nurse recall group v audit group: difference 10% (95% confidence interval 3% to 17%; P=0.009); GP recall group v audit group: difference 2% (−6% to 10%; P=0.61); nurse recall group v GP recall group: difference 8% (1% to 15%; P=0.031).